This phase III trial studies how well curcumin works in preventing progression in patients with prostate cancer that is limited to the prostate and who are undergoing active surveillance. This study is being done to determine if curcumin decreases the likelihood of cancer progressing in men undergoing active surveillance for prostate cancer.
Additional locations may be listed on ClinicalTrials.gov for NCT03769766.
Locations matching your search criteria
United States
Texas
Dallas
UT Southwestern/Simmons Cancer Center-DallasStatus: Active
Contact: Yair Lotan
Phone: 214-648-0389
PRIMARY OBJECTIVES:
I. To determine if the use of bio-enhanced curcumin extract formulation (curcumin) randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive curcumin orally (PO) twice daily (BID) for 24 months in the absence of disease progression or unacceptable toxicity.
GROUP II: Patients receive placebo PO BID for 24 months in the absence of disease progression or unacceptable toxicity.
Patients are followed up for 3 years after study entry.
Lead OrganizationUT Southwestern/Simmons Cancer Center-Dallas
Principal InvestigatorYair Lotan
